The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.
The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.
The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.
The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.